ArticleJournal of pharmacy & bioallied sciences2024
Comprehensive Analysis of Intermittent Fasting on Anthropometric Indices, Glycemic Control, and Serum Insulin Levels in Obese Patients with Type 2 Diabetes.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intermittent fasting to treat diabetes: time to update clinical practice guidelines.The lancet. Diabetes & endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes significantly impacts socioeconomic conditions, with periods of obesity and insulin resistance preceding diagnosis. Fasting, practiced for millennia, offers the potential to manage and possibly reverse diabetes. This study aims to assess the effects of intermittent fasting on various health indicators in obese type 2 diabetic patients. Methodology: Thirty obese volunteers with type 2 diabetes mellitus, uncontrolled by metformin alone, aged 20-60, were included. They followed a 16:8 intermittent fasting regimen for four weeks. Initial and postintervention measurements included height, weight, BMI, waist-hip ratio, waist circumference, fasting blood sugar, and serum insulin. Results were compared using the student Results: After four weeks, significant reductions were observed in anthropometric indices and fasting blood sugar, but no change in serum insulin levels. Conclusion: A 16:8 intermittent fasting regimen significantly reduced fasting blood glucose levels and anthropometric indices in obese type 2 diabetes patients over four weeks, with no effect on serum insulin levels. Larger and longer-term studies are needed to explore long-term effects and mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.